Addendum
Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Addendum to Project A25-155
Report documents
-
Addendum
Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Addendum to Project A25-155
Dossier assessment
Indication:
Adult patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation; adjuvant treatment
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
05-06-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-44
- Commission
- Commission awarded on 29.04.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-44_V1.1_en
Connected Projects
-
Dossier assessment
Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed